Pigmentation Disorder Treatment Market

Pigmentation Disorder Treatment Market (Treatment: Topical Drugs, Laser Therapy, Chemical Peels, Microdermabrasion, Phototherapy, and Others) Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Pigmentation Disorder Treatment Market Outlook 2031

  • The global industry was valued at US$ 6.8 Bn in 2022
  • It is estimated to grow at a CAGR of 5.2% from 2023 to 2031 and reach US$ 10.6 Bn by the end of 2031

Analyst Viewpoint

Increase in adoption of advanced skincare procedures, led by rise in awareness about skin conditions among the global population, is a key factor that is bolstering the pigmentation disorder treatment market size. Surge in pigmentation cases owing to excessive exposure to sun, skin injuries, and inflammation is also augmenting market progress. People are increasingly opting for skin treatments such as laser therapy and chemical peels, as these are safer and offer quicker results. However, high cost of these treatments is hampering the pigmentation disorder treatment industry revenue to some extent.

Companies operating in the sector are launching novel drugs and therapies to expand their client base. In line with the latest pigmentation disorder treatment market trends, key players are striving to introduce advanced treatment modalities to improve the outcome of these procedures.

Pigmentation Disorder Treatment Market

Market Introduction

Pigmentation is a skin condition that adversely affects the color of the skin. Melasma, albinism, and vitiligo are some of the common types of pigmentation disorders. Skin pigmentation can occur in patches or across the body.

Albinism, a genetic disorder, is caused by defects in genes that provide instructions for melanin production. Body is unable to produce or distribute melanin due to several genetic defects. Lack of color in skin, hair, or eyes is the primary symptom of albinism.

Melasma, a common skin pigmentation disorder, is also referred to as chloasma or the ‘mask of pregnancy.’ It is a common skin condition that usually affects women. People with darker skin tones are more likely to be affected by melasma.

Discoloration of skin can also occur due to skin damage. Burns and wounds can result in skin pigmentation that is permanent or long-lasting, depending upon the severity.

Increase in Adoption of Advanced Medical Procedures Fueling Pigmentation Disorder Treatment Market Growth

Adoption of advanced medical procedures, such as skin treatments, has been rising across the globe, as people are increasingly upgrading their lifestyle. Rise in disposable income is also leading to a growth in adoption of advanced medical treatments. Furthermore, increase in awareness about skin disorders is creating lucrative pigmentation disorder treatment business opportunities for companies operating in the sector.

Several types of pigmentation disorder treatments such as laser therapy, chemical peels, and micro-needling have been introduced lately in the market. These are quite safe and offer improved and quick results. For instance, utilization of latest picosecond laser has boosted the pigmentation disorder treatment industry. Ultra-short light pulses from picosecond lasers can precisely target and remove pigment particles from the pigmented area without damaging or harming the surrounding skin.

Compared to conventional nanosecond lasers, these lasers have lesser side effects, quicker treatment periods, and greater efficacy, which has made them quite popular. Thus, rise in adoption of newer and advanced skin treatments is boosting pigmentation disorder treatment market dynamics.

Rise in Prevalence of Pigmentation Cases and Growth in R&D Initiatives

According to Karger Journal study, people from Latin America and African heritage are more prone to pigmentation disorders. Significant population in Asia Pacific, especially in China and India, also faces high incidence of pigmentation problems.

The Karger journal study further states that pigmentation disorders rank third and fourth among dermatoses, which largely affects the Hispanic population.

The global pigmentation disorder treatment market is expected to grow at a steady pace in the near future due to increase in research and development initiatives by key players. For instance, in July 2022, Ahammune Biosciences and Veeda Clinical Research Limited entered into a partnership for first-in-human studies with Ahammune’s investigational new drug -AB1001 - being developed as a topical therapy for vitiligo.

Rise in government investment in healthcare and biotechnology industries in developing countries is also likely to augment the pigmentation disorder treatment market during the forecast period.

Regional Outlook

Asia Pacific accounted for significant pigmentation disorder treatment market share in 2022. People in the region are more inclined to seek treatment for pigmentation disorders as a result of growth in concerns about skin and appearance and rise in disposable income.

Several countries in Asia Pacific have been experiencing rapid urbanization, which has led to changes in lifestyle and increase in exposure to environmental factors such as pollution, high temperatures, and even global warming that might worsen pigmentation issues.

People living in the urban areas in Asia Pacific have easy access to healthcare facilities and dermatologists. Increase in awareness about skin health, presence of developed healthcare facilities, and availability of modern medical treatments are also augmenting market statistics in Asia Pacific.

Analysis of Key Players

Leading pigmentation disorder treatment market manufacturers are investing significantly in the manufacture of highly effective skincare products to expand their product portfolio and increase their industry share. They are also engaged in clinical trials to develop drugs and treatments that reduce discoloration by protecting the skin from external aggressors.

Bayer AG, Galderma S.A. (Nestle Skin Health S.A), SkinCeuticals, Pierre Fabre, EpiPharm AG, RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), and Vivier Pharma are some of the prominent manufacturers of pigmentation disorder treatment drugs.

Each of these players has been profiled in the pigmentation disorder treatment market report based on parameters such as company overview, business strategies, financial overview, business segments, product portfolio, and recent developments.

Key Developments

  • In July 2022, Incyte Corporation received an approval from the United States Food and Drug Administration for Opzelura (ruxolitinib) cream for treating non-segmental vitiligo in adults and even for kids of 12 years of age and older.

Pigmentation Disorder Treatment Market Snapshot

Attribute Detail
Market Size in 2022 US$ 6.8 Bn
Market Forecast (Value) in 2031 US$ 10.6 Bn
Growth Rate (CAGR) 5.2%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional-level analysis. Furthermore, the qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes an overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Treatment
    • Topical Drugs
    • Laser Therapy
    • Chemical Peels
    • Microdermabrasion
    • Phototherapy
    • Others
  • Disease Indication
    • Hypopigmentation
      • Vitiligo
      • Albinism
      • Others
    • Hyperpigmentation
      • Melasma
      • Post-inflammatory Hyperpigmentation
      • Solar Lentigines
      • Others
  • End-user
    • Hospitals
    • Aesthetic Clinics & Dermatology Centers
    • Others
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia and CIS
  • Japan
  • China
  • India
  • ASIAN
  • Brazil
  • Mexico
  • GCC
  • South Africa
Companies Profiled
  • Bayer AG
  • Galderma S.A. (Nestle Skin Health S.A)
  • SkinCeuticals
  • Pierre Fabre
  • EpiPharm AG
  • RXi Pharmaceuticals Corporation
  • Obagi Cosmeceuticals LLC (Obagi Medical)
  • Vivier Pharma
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global pigmentation disorder treatment market in 2022?

It was valued at US$ 6.8 Bn in 2022

How is the pigmentation disorder treatment business expected to grow by 2031?

It is anticipated to grow at a CAGR of 5.2% from 2023 to 2031

What are the key factors driving the demand for pigmentation disorder treatment?

Increase in adoption of advanced medical procedures, rise in prevalence of pigmentation cases, and growth in R&D initiatives

Which was the largest pigmentation disorder treatment segment in 2022?

The topical drugs treatment segment held the largest share in 2022

Which was the major region in the global pigmentation disorder treatment landscape in 2022?

Asia Pacific was the leading region in 2022

Who are the key pigmentation disorder treatment drugs manufacturers?

Bayer AG, Galderma S.A. (Nestle Skin Health S.A.), SkinCeuticals, Pierre Fabre, EpiPharm AG, RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC (Obagi Medical), Vivier Pharma

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Pigmentation Disorder Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Pigmentation Disorder Treatment Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Treatment

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Treatment, 2017–2031

            6.3.1. Topical Drugs

            6.3.2. Laser Therapy

            6.3.3. Chemical Peels

            6.3.4. Microdermabrasion

            6.3.5. Phototherapy

            6.3.6. Others

        6.4. Market Attractiveness Analysis, by Treatment

    7. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Disease Indication

        7.1. Introduction & Definition

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Disease Indication, 2017–2031

            7.3.1. Hypopigmentation

                7.3.1.1. Vitiligo

                7.3.1.2. Albinism

                7.3.1.3. Others

            7.3.2. Hyperpigmentation

                7.3.2.1. Melasma

                7.3.2.2. Post-inflammatory Hyperpigmentation

                7.3.2.3. Solar Lentigines

                7.3.2.4. Others

        7.4. Market Attractiveness Analysis, by Disease Indication

    8. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by End-user

        8.1. Introduction & Definition

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by End-user, 2017–2031

            8.3.1. Hospitals

            8.3.2. Aesthetic Clinics & Dermatology Centers

            8.3.3. Others

        8.4. Market Attractiveness Analysis, by Disease Indication

    9. Global Pigmentation Disorder Treatment Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region, 2017–2031

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Pigmentation Disorder Treatment Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Treatment, 2017–2031

            10.3.1. Topical Drugs

            10.3.2. Laser Therapy

            10.3.3. Chemical Peels

            10.3.4. Microdermabrasion

            10.3.5. Phototherapy

            10.3.6. Others

        10.4. Market Value Forecast, by Disease Indication, 2017–2031

            10.4.1. Hypopigmentation

                10.4.1.1. Vitiligo

                10.4.1.2. Albinism

                10.4.1.3. Others

            10.4.2. Hyperpigmentation

        10.5. Melasma

            10.5.1. Post-inflammatory Hyperpigmentation

            10.5.2. Solar Lentigines

            10.5.3. Others

        10.6. Market Value Forecast, by End-user, 2017–2031

            10.6.1. Hospitals

            10.6.2. Aesthetic Clinics & Dermatology Centers

            10.6.3. Others

        10.7. Market Value Forecast, by Country, 2017–2031

            10.7.1. U.S.

            10.7.2. Canada

        10.8. Market Attractiveness Analysis

            10.8.1. By Treatment

            10.8.2. By Disease Indication

            10.8.3. By End-user

            10.8.4. By Country

    11. Europe Pigmentation Disorder Treatment Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Treatment, 2017–2031

            11.3.1. Topical Drugs

            11.3.2. Laser Therapy

            11.3.3. Chemical Peels

            11.3.4. Microdermabrasion

            11.3.5. Phototherapy

            11.3.6. Others

        11.4. Market Value Forecast, by Disease Indication, 2017–2031

            11.4.1. Hypopigmentation

                11.4.1.1. Vitiligo

                11.4.1.2. Albinism

                11.4.1.3. Others

            11.4.2. Hyperpigmentation

                11.4.2.1. Melasma

                11.4.2.2. Post-inflammatory Hyperpigmentation

                11.4.2.3. Solar Lentigines

                11.4.2.4. Others

        11.5. Market Value Forecast, by End-user, 2017–2031

            11.5.1. Hospitals

            11.5.2. Aesthetic Clinics & Dermatology Centers

            11.5.3. Others

        11.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.6.1. Germany

            11.6.2. U.K.

            11.6.3. France

            11.6.4. Italy

            11.6.5. Spain

            11.6.6. Rest of Europe

        11.7. Market Attractiveness Analysis

            11.7.1. By Treatment

            11.7.2. By Disease Indication

            11.7.3. By End-user

            11.7.4. By Country/Sub-region

    12. Asia Pacific Pigmentation Disorder Treatment Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Treatment, 2017–2031

            12.3.1. Topical Drugs

            12.3.2. Laser Therapy

            12.3.3. Chemical Peels

            12.3.4. Microdermabrasion

            12.3.5. Phototherapy

            12.3.6. Others

        12.4. Market Value Forecast, by Disease Indication, 2017–2031

            12.4.1. Hypopigmentation

                12.4.1.1. Vitiligo

                12.4.1.2. Albinism

                12.4.1.3. Others

            12.4.2. Hyperpigmentation

                12.4.2.1. Melasma

                12.4.2.2. Post-inflammatory Hyperpigmentation

                12.4.2.3. Solar Lentigines

                12.4.2.4. Others

        12.5. Market Value Forecast, by End-user, 2017–2031

            12.5.1. Hospitals

            12.5.2. Aesthetic Clinics & Dermatology Centers

            12.5.3. Others

        12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.6.1. China

            12.6.2. Japan

            12.6.3. India

            12.6.4. Australia & New Zealand

            12.6.5. Rest of Asia Pacific

        12.7. Market Attractiveness Analysis

            12.7.1. By Treatment

            12.7.2. By Disease Indication

            12.7.3. By End-user

            12.7.4. By Country/Sub-region

    13. Latin America Pigmentation Disorder Treatment Market Analysis and Forecast

        13.1. Introduction

        13.2. Key Findings

        13.3. Market Value Forecast, by Treatment, 2017–2031

            13.3.1. Topical Drugs

            13.3.2. Laser Therapy

            13.3.3. Chemical Peels

            13.3.4. Microdermabrasion

            13.3.5. Phototherapy

            13.3.6. Others

        13.4. Market Value Forecast, by Disease Indication, 2017–2031

            13.4.1. Hypopigmentation

                13.4.1.1. Vitiligo

                13.4.1.2. Albinism

                13.4.1.3. Others

            13.4.2. Hyperpigmentation

                13.4.2.1. Melasma

                13.4.2.2. Post-inflammatory Hyperpigmentation

                13.4.2.3. Solar Lentigines

        13.5. Others

        13.6. Market Value Forecast, by End-user, 2017–2031

            13.6.1. Hospitals

            13.6.2. Aesthetic Clinics & Dermatology Centers

            13.6.3. Others

        13.7. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.7.1. Brazil

            13.7.2. Mexico

            13.7.3. Rest of Latin America

        13.8. Market Attractiveness Analysis

            13.8.1. By Treatment

            13.8.2. By Disease Indication

            13.8.3. By End-user

            13.8.4. By Country/Sub-region

    14. Middle East & Africa Pigmentation Disorder Treatment Market Analysis and Forecast

        14.1. Introduction

        14.2. Key Findings

        14.3. Market Value Forecast, by Treatment, 2017–2031

            14.3.1. Topical Drugs

            14.3.2. Laser Therapy

            14.3.3. Chemical Peels

            14.3.4. Microdermabrasion

            14.3.5. Phototherapy

            14.3.6. Others

        14.4. Market Value Forecast, by Disease Indication, 2017–2031

            14.4.1. Hypopigmentation

                14.4.1.1. Vitiligo

                14.4.1.2. Albinism

                14.4.1.3. Others

            14.4.2. Hyperpigmentation

                14.4.2.1. Melasma

                14.4.2.2. Post-inflammatory Hyperpigmentation

                14.4.2.3. Solar Lentigines

                14.4.2.4. Others

        14.5. Market Value Forecast, by End-user, 2017–2031

            14.5.1. Hospitals

            14.5.2. Aesthetic Clinics & Dermatology Centers

            14.5.3. Others

        14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.6.1. GCC Countries

            14.6.2. South Africa

            14.6.3. Rest of Middle East & Africa

        14.7. Market Attractiveness Analysis

            14.7.1. By Treatment

            14.7.2. By Disease Indication

            14.7.3. By End-user

            14.7.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        15.2. Market Share Analysis, by Company (2022)

        15.3. Company Profiles

            15.3.1. Bayer AG

                15.3.1.1. Company Overview

                15.3.1.2. Product Portfolio

                15.3.1.3. SWOT Analysis

                15.3.1.4. Financial Overview

                15.3.1.5. Strategic Overview

            15.3.2. Galderma S.A. (Nestle Skin Health S.A)

                15.3.2.1. Company Overview

                15.3.2.2. Product Portfolio

                15.3.2.3. SWOT Analysis

                15.3.2.4. Financial Overview

                15.3.2.5. Strategic Overview

            15.3.3. SkinCeuticals

                15.3.3.1. Company Overview

                15.3.3.2. Product Portfolio

                15.3.3.3. SWOT Analysis

                15.3.3.4. Financial Overview

                15.3.3.5. Strategic Overview

            15.3.4. Pierre Fabre

                15.3.4.1. Company Overview

                15.3.4.2. Product Portfolio

                15.3.4.3. SWOT Analysis

                15.3.4.4. Financial Overview

                15.3.4.5. Strategic Overview

            15.3.5. EpiPharm AG

                15.3.5.1. Company Overview

                15.3.5.2. Product Portfolio

                15.3.5.3. SWOT Analysis

                15.3.5.4. Financial Overview

                15.3.5.5. Strategic Overview

            15.3.6. RXi Pharmaceuticals Corporation

                15.3.6.1. Company Overview

                15.3.6.2. Product Portfolio

                15.3.6.3. SWOT Analysis

                15.3.6.4. Financial Overview

                15.3.6.5. Strategic Overview

            15.3.7. Obagi Cosmeceuticals LLC (Obagi Medical)

                15.3.7.1. Company Overview

                15.3.7.2. Product Portfolio

                15.3.7.3. SWOT Analysis

                15.3.7.4. Financial Overview

                15.3.7.5. Strategic Overview

            15.3.8. Vivier Pharma

                15.3.8.1. Company Overview

                15.3.8.2. Product Portfolio

                15.3.8.3. SWOT Analysis

                15.3.8.4. Financial Overview

                15.3.8.5. Strategic Overview

    List of Tables

    Table 01: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 02: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 03: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 04: Global Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 07: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 08: North America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 09: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 11: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 12: Europe Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 13: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 15: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 16: Asia Pacific Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 17: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 19: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 20: Latin America Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    Table 21: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2031

    Table 23: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2017–2031

    Table 24: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2031

    List of Figures

    Figure 01: Global Pigmentation Disorder Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031

    Figure 02: Global Pigmentation Disorder Treatment Market Revenue (US$ Mn), by Treatment, 2022

    Figure 03: Global Pigmentation Disorder Treatment Market Value Share, by Treatment, 2022

    Figure 04: Global Pigmentation Disorder Treatment Market Revenue (US$ Mn), by Disease Indication, 2022

    Figure 05: Global Pigmentation Disorder Treatment Market Value Share, by Disease Indication, 2022

    Figure 06: Global Pigmentation Disorder Treatment Market Revenue (US$ Mn), by End-user, 2022

    Figure 07: Global Pigmentation Disorder Treatment Market Value Share, by End-user, 2022

    Figure 08: Global Pigmentation Disorder Treatment Market Value Share, by Region, 2022

    Figure 09: Global Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 10: Global Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031

    Figure 11: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017-2031

    Figure 12: Global Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031

    Figure 13: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2022-2031

    Figure 14: Global Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031

    Figure 15: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017-2031

    Figure 16: Global Pigmentation Disorder Treatment Market Value Share Analysis, by Region, 2017 and 2031

    Figure 17: Global Pigmentation Disorder Treatment Market Attractiveness Analysis, by Region, 2017-2031

    Figure 18: North America Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 19: North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country, 2017–2031

    Figure 20: North America Pigmentation Disorder Treatment Market Value Share Analysis, by Country, 2017 and 2031

    Figure 21: North America Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031

    Figure 22: North America Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031

    Figure 23: North America Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031

    Figure 24: North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017–2031

    Figure 25: North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2031

    Figure 26:North America Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2022–2031

    Figure 27: Europe Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 28: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 29: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 30: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031

    Figure 31: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031

    Figure 32: Europe Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031

    Figure 33: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017–2031

    Figure 34: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2031

    Figure 35: Europe Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017–2031

    Figure 36: Asia Pacific Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 37: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 38: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 39: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031

    Figure 40: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031

    Figure 41: Asia Pacific Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031

    Figure 42: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017–2031

    Figure 43: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2031

    Figure 44: Asia Pacific Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017–2031

    Figure 45: Latin America Pigmentation Disorder Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 46: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 47: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 48: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031

    Figure 49: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031

    Figure 50: Latin America Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031

    Figure 51: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017–2031

    Figure 52: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2031

    Figure 53: Latin America Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017–2031

    Figure 54: Middle East & Africa Pigmentation Disorder Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 55: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 56: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2031

    Figure 57: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by Treatment, 2017 and 2031

    Figure 58: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by Disease Indication, 2017 and 2031

    Figure 59: Middle East & Africa Pigmentation Disorder Treatment Market Value Share Analysis, by End-user, 2017 and 2031

    Figure 60: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by Treatment, 2017–2031

    Figure 61: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2031

    Figure 62: Middle East & Africa Pigmentation Disorder Treatment Market Attractiveness Analysis, by End-user, 2017–2031

Copyright © Transparency Market Research, Inc. All Rights reserved